LEADER 05361nam 22015613a 450 001 9910346684303321 005 20250203235429.0 010 $a9783039210619 010 $a3039210610 024 8 $a10.3390/books978-3-03921-061-9 035 $a(CKB)4920000000094826 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/54029 035 $a(ScCtBLL)9b5b364c-2670-4301-9845-c4b9a0365ea7 035 $a(OCoLC)1117844310 035 $a(oapen)doab54029 035 $a(EXLCZ)994920000000094826 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$amTOR in Human Diseases$fOlivier Dormond 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (480 p.) 311 08$a9783039210602 311 08$a3039210602 330 $aThe mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies. 606 $aMedicine$2bicssc 610 $aprimary cilia 610 $aneurodegeneration 610 $anutrient sensor 610 $aPI3K 610 $atranscriptomics 610 $aphosphorylation 610 $ametabolic reprogramming 610 $aautophagy 610 $aAlzheimer's disease 610 $arapalogs 610 $aliver 610 $aangiogenesis 610 $amTOR complex 610 $aMBSCs 610 $aadvanced biliary tract cancers 610 $aMedulloblastoma 610 $aepithelial to mesenchymal transition 610 $aAMPK 610 $ap70S6K 610 $alipid metabolism 610 $athyroid cancer 610 $asodium iodide symporter (NIS)/SLC5A5 610 $amale fertility 610 $aanesthesia 610 $aillumina 610 $amTOR inhibitor 610 $amiRNA 610 $aHutchinson-Gilford progeria syndrome (HGPS) 610 $aeIFs 610 $aEmery-Dreifuss muscular dystrophy (EDMD) 610 $aglucose 610 $aAKT 610 $aoral cavity squamous cell carcinoma (OSCC) 610 $aglucose and lipid metabolism 610 $acellular signaling 610 $aaging 610 $atumor microenvironment 610 $arapamycin 610 $aleukemia 610 $achloral hydrate 610 $arapalogues 610 $aschizophrenia 610 $aT-cell acute lymphoblastic leukemia 610 $asenescence 610 $alamin A/C 610 $aneurotoxicity 610 $aneurodevelopment 610 $ainhibitor 610 $amethamphetamine 610 $apulmonary fibrosis 610 $amTOR 610 $amTOR inhibitors 610 $acombination therapy 610 $aproteolysis 610 $afluid shear stress 610 $atumour cachexia 610 $abiomarkers 610 $asynapse 610 $agluconeogenesis 610 $amTOR signal pathway 610 $aSertoli cells 610 $aimmunosenescence 610 $amiRNome 610 $aprotein aggregation 610 $asenolytics 610 $ametabolism 610 $aNGS 610 $amTORC2 610 $amTORC1 610 $ametabolic diseases 610 $aIonTorrent 610 $aapoptosis 610 $adopamine receptor 610 $anocodazole 610 $amicroenvironment 610 $aeverolimus 610 $aacute myeloid leukemia 610 $aimmunotherapy 610 $aspermatogenesis 610 $abone remodeling 610 $asignalling 610 $atargeted therapy 610 $aageing 610 $atherapy 610 $aNVP-BEZ235 610 $afructose 610 $aphysical activity 610 $alaminopathies 610 $aMC3T3-E1 cells 610 $acell signaling 610 $amicroRNA 610 $acancer 610 $alipolysis 610 $amelatonin 610 $aParkinson's disease 615 7$aMedicine 700 $aDormond$b Olivier$01331033 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910346684303321 996 $aMTOR in Human Diseases$93040048 997 $aUNINA